Safety worries mar mid-stage data for Huntingdon's candidate

6 January 2022

Shares in Californian autoimmune specialist Annexon (Nasdaq: ANNX) slumped over 40% on Wednesday, after the firm announced interim Phase II data for its Huntington’s disease candidate ANX005.

While the company described the results as “promising” and indicated that the therapy was “generally well tolerated,” investors appear to have been spooked by the number of dropouts from the trial.

Five people discontinued treatment in the study, out of 28 participants, with three of those due to treatment-related adverse events.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK